Quick Facts

• Primary Use: Management of functional gastrointestinal symptoms.
• Associated Conditions: Irritable bowel syndrome and peptic ulcer disease.
• Symptom Relief: Addresses abdominal discomfort, including fullness, bloating, and cramping.
• Additional Use: Provides relief from symptoms of dysmenorrhea.

---

Avarin is a recognized therapeutic option for the symptomatic management of certain gastrointestinal (GI) disorders. It is indicated for use in individuals experiencing functional GI discomfort, which includes conditions such as irritable bowel syndrome and symptoms associated with peptic ulcer disease. The medication is designed to assist in addressing abdominal discomfort, which may manifest as pain, pressure, bloating, fullness, distension, and cramping.

In addition to its role in GI disorders, Avarin also offers relief from symptoms of dysmenorrhea (painful menstruation). The therapeutic action of Avarin is focused on helping to ease smooth muscle spasms within the digestive tract and managing excess gas, which may lead to observable improvement in associated symptoms. This medication is indicated for these uses.

Who Can and Cannot Use Avarin?

The population eligibility for Avarin (Alverine/Simethicone) is defined by strict regulatory standards, primarily focusing on patient age, physical condition, and physiological status. The medicine is primarily intended for use in adults and older adults.

---

Absolute Regulatory Exclusions

Use of Avarin is contraindicated and must be avoided in several specific populations and conditions, as stated in official regulatory labeling:

• Pediatric Age: Contraindicated for children under 12 years of age.
• Hypersensitivity: Patients with known allergy or hypersensitivity to Alverine, Simethicone, or any of the product's excipients.
• Gastrointestinal Obstruction: Individuals with a diagnosis of intestinal obstruction or paralytic ileus.
• Reproductive Status: Pregnant and lactating (breastfeeding) women.

---

Restrictions and Conditional Use

Official labeling identifies populations where use is either not recommended or requires special consideration, though these are not absolute contraindications:

• Hypotension: The medicine should not be recommended for administration to hypotensive patients (those with low blood pressure).

There are no specific contraindications documented for patients with mild to moderate hepatic impairment or renal impairment in the regulatory labeling.

Interactions with other medicines and products

Avarin is a combination product containing alverine citrate (an antispasmodic) and simethicone (an antiflatulent). Information regarding clinically significant drug interactions for this specific combination product is limited in regulatory documentation.

Documented Interaction Profile

The official Summary of Product Characteristics for this combination generally states that no known interactions with other medicinal products exist. The lack of an established interaction list is attributed to the mechanism and minimal absorption of its components:

• Simethicone is considered to be physiologically inert and is not absorbed from the gastrointestinal tract, meaning it is not expected to interfere with the absorption or metabolism of most systemic medications. However, due to its physical properties, it may reduce the absorption of certain orally administered drugs, such as levothyroxine (used for thyroid disorders). It is generally advised to separate the timing of administration for these types of medicines.

• Alverine citrate is rapidly metabolized after oral administration. While official labeling often states 'none known,' alverine's primary active metabolite acts as a smooth muscle relaxant. Other substances that cause central nervous system (CNS) depression, such as certain sedatives, tranquilizers, or alcohol, may theoretically enhance effects like dizziness or drowsiness when taken concurrently with alverine, though this specific interaction is often inferred rather than explicitly listed in all official product information.

Interaction-Related Constraints

Consultation with a healthcare professional is necessary before combining this product with other prescription or over-the-counter medications to ensure the treatment plan remains safe and effective.

Modulating Gastrointestinal Smooth Muscle Activity

The Alverine component engages molecular mechanisms to modulate physiological responses. Its core action involves the blockade of Voltage-Gated Ca^2+ Channels in the smooth muscle cells, which inhibits the influx of calcium ions required for cellular contraction. This action initiates a molecular cascade resulting in decreased smooth muscle tone and modulation of peristaltic activity. Additionally, Alverine acts as an antagonist at the 5-Hydroxytryptamine Receptor 1A (5-, HT1A), a pathway involved in visceral sensory nociception, which modulates the transmission of afferent signals from the gut wall.

Physical Alteration of Intraluminal Gas Dynamics

The Simethicone component is an inert polymer that operates entirely through a physical mechanism within the gut lumen, which modifies surface dynamics. It acts as a surfactant, significantly reducing the surface tension of the small gas bubbles trapped in the intestinal contents. This process causes the small bubbles to coalesce into larger gas pockets that exhibit altered intraluminal mobility. This action modifies the physical properties of intraluminal foam.

How to Use Avarin: Official Administration Guidelines

Avarin is a fixed-dose combination medicine containing 60 mg Alverine Citrate and 300 mg Simethicone per unit, formulated as a Soft Gel Capsule for oral administration. The official use of this medicine is defined by guidelines which establish procedures for its intake and dosage.

---

Administration Scope

The medicine is taken via the oral route, with the capsule administered one to three times daily. A specific procedural constraint requires that the administration occur after meals. The maximum daily dose is three capsules in a 24-hour period (180 mg Alverine / 900 mg Simethicone).

Preparation requirements dictate that the soft gel capsule must be swallowed whole with an adequate amount of liquid and must not be broken or chewed. This ensures the delivery of the fixed combination of ingredients as intended by the manufacturer's formulation.

---

Administration Rules for Specific Populations

Official labeling addresses the use of this medicine for certain groups:

Population Group	Administration Rule
Paediatric	Not applicable; contraindicated for use in children under 12 years old.
Older Adults	The standard adult dosing regimen applies.

Should a scheduled dose be missed, established guidelines instruct that it should be taken when remembered, unless it is nearly time for the next scheduled dose. Users are specifically cautioned that a double dose must not be taken to compensate for the missed administration.

These official instructions govern the standardized oral use protocol, defining the dose range, frequency, and conditions of intake for the fixed-dose combination.

Avarin: Overview of Research Evidence

---

Evidence for Use in Functional Gastrointestinal (GI) Discomfort

Research has explored Avarin as a fixed-dose combination in the context of functional digestive distress. Studies, including short-term Randomized Controlled Trials (RCTs), focused on measuring changes in patient-reported outcomes related to physical discomfort, specifically abdominal pain, cramping, bloating, and fullness. The findings describe patterns observed in these studies where measurements of these functional symptoms were taken, contributing to understanding symptom patterns related to gas accumulation and smooth muscle spasms.

Evidence for Use in Irritable Bowel Syndrome (IBS)

Avarin was studied for use in people diagnosed with Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating symptoms. Research explored short-term symptom changes in populations meeting IBS criteria, focusing on measuring outcomes related to systemic or functional imbalance such as abdominal pain and bloating. The research highlights changes measured during the study period in participants with IBS. Comparative trials provided data show patterns related to how symptom severity evolved when compared against a placebo or other therapeutic options.

What Research Gaps and Uncertainties Remain

The current evidence base is largely derived from studies with limited follow-up durations. Consequently, long-term effects are not fully established regarding sustained patterns of relief. Evidence quality varies across studies, and sample sizes were modest in some pivotal trials, meaning the results apply only to the populations studied under those specific conditions. Comparative evidence is lacking for some outcomes when evaluated against alternative treatments, and data for certain groups remain insufficient regarding children or older adults.

Key Studies & References Alverine Citrate (DB09062)

How to Store and Dispose of Avarin

Avarin (Simethicone 300 mg and Alverine Citrate 60 mg Soft Gel Capsule) must be stored according to official regulatory requirements to ensure stability.

Storage Conditions

Storage of the medicine must be maintained at a temperature not exceeding 30 C. It is mandatory to store the capsules in a dry place and away from direct sunlight to protect them from light and moisture degradation. Avarin must also be kept out of sight and reach of children.

Stability and Disposal

The medicine must not be used after the expiry date or if the capsules show any significant changes in appearance. For disposal, unused or expired Avarin should not be thrown away with household waste or wastewater. Instead, it should be returned to a pharmacist for appropriate pharmaceutical waste handling.